Green Leaf Pharmaceuticals (02186.HK): If the Phase III clinical trial of Xinxinlin for the treatment of generalized anxiety disorder in China is completed, all patients will be enrolled.

Wisdom Finance and Economics APP news, Luye Pharma (02186.HK) announced that the group's independently developed innovative drug Roxilin (Tolterodine Tartrate and Flavoxate Hydrochloride Sustained-release Tablets) for the treatment of generalized anxiety disorder has completed all of the patients' recruitment for the Phase III clinical trial.